Gara Jalqabaatti › Dhukkuba Kroonii › New York › New York City
Qorannoo klinikaalii Dhukkuba Kroonii New York City, NY keessatti
Qorannoo 35 Dhukkuba Kroonii f New York City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Namoota walitti qabaa jiraSadarkaa 2
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Namoota walitti qabaa jiraSadarkaa 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Namoota walitti qabaa jiraSadarkaa 3
- New York Gastroenterology Associates ( Site 0253), New York
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Namoota walitti qabaa jiraSadarkaa 3
- NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078), New York
- Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079), New York
- New York Gastroenterology Associates ( Site 5013), New York
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Namoota walitti qabaa jiraSadarkaa 4
- New York Gastroenterology Associates, New York
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 2
- Northwell Health-Lenox Hill Hospital /ID# 265527, New York
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 3
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 2
- Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 3
- New York Gastroenterology Associates, New York
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 2/3
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Weill Cornell Medical College, New York
- Lenox Hill Hospital, New York
- fi 1 dabalataa
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Namoota walitti qabaa jiraSadarkaa 3
- New York Gastroenterology Associates, New York
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 3
- Manhattan Clinical Research, LLC-Site Number: 8400069, New York
- NYU Langone Health-Site Number: 8400091, New York
- Columbia University Medical Center-Site Number: 8400138, New York
- fi 2 dabalataa
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 3
- NYU Langone Health-Site Number: 8400091, New York
- Weill Cornell Medicine - NewYork-Presbyterian Hospital-Site Number: 8400040, New York
- New York Gastroenterology Associates-Site Number: 8400009, New York
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 3
- Icahn School of Medicine at Mount Sinai /ID# 254880, New York
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Namoota walitti qabaa jiraSadarkaa 3
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 4
- NYU Langone Health, New York
Standardized Microbiota Transplant Therapy in Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 2
- NYU Langone Health, New York
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 3
- New York Gastroenterology Associates, New York
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 3
- Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center/New York Presbyterian, New York
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 3
- Weill Cornell Medicine, New York
Behavioral Therapy for Crohn's Disease
Namoota walitti qabaa jira
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Namoota walitti qabaa jira
- NYU Langone Health, New York
- Cornell University, New York
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Namoota walitti qabaa jiraQorannoo ilaalaa
- New York University, New York
Low Dose IL-2 for the Treatment of Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 1/2
- Mount Sinai, New York
Autologous Stem Cell Transplant for Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 2
- Icahn School of Medicine at Mount Sinai, New York
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 3
- Icahn School of Medicine at Mount Sinai /ID# 262216, New York
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Namoota walitti qabaa jiraSadarkaa 3
- New York Presbyterian Hospital, New York
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 3
- Columbia University Medical Center, New York-Presbyterian Hospital, New York
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 4
- Columbia University Medical Center, New York
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
Namoota walitti qabaa jira
- Weill Cornell Medical College, New York
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Namoota walitti qabaa jiraSadarkaa 2
- Mirador Therapeutics Selected Site, New York
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Icahn School of Medicine at Mount Sinai, New York
Treatment of Moderate to Severe Refractory Crohn's Disease
Namoota walitti qabaa jiraSadarkaa 1/2
- Mount Sinai Health Systems, New York
Helmsley 3.0: Abbreviated MRE
Namoota walitti qabaa jiraQorannoo ilaalaa
- NYU Langone, New York
Qorannoo Dhukkuba Kroonii magaalota biroo keessatti
- Boston, MAQorannoo 19
- Miami, FLQorannoo 19
- Cleveland, OHQorannoo 19
- St. Louis, MOQorannoo 19
- Tyler, TXQorannoo 17
- Houston, TXQorannoo 17
- Orlando, FLQorannoo 17
- Atlanta, GAQorannoo 17
- San Antonio, TXQorannoo 15
- San Diego, CAQorannoo 15
- Los Angeles, CAQorannoo 15
- Colorado Springs, COQorannoo 13
Qorannoo biroo New York City keessatti
- Saree OljooQorannoo 136
- Kansara Qara'a Non-Small CellQorannoo 121
- Saree (Gosoota Hunda)Qorannoo 109
- Kansarii ProstateQorannoo 103
- Kansara MetastatikiiQorannoo 93
- Kansarii ColorectalQorannoo 78
- Kansarii OvariiQorannoo 69
- Dhibee QaraQorannoo 60
- Myeloma Baay’eeQorannoo 60
- Kansarii PancreasQorannoo 60
- Kansa EndometiriyaaliiQorannoo 52
- Leukemia Myeloidii HamaaQorannoo 51
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.